Pembrolizumab Injection

Phase 2Terminated

2 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neuroendocrine Tumors

Conditions

Neuroendocrine Tumors

Trial Timeline

Dec 4, 2017 → Mar 11, 2019

NCT ID

NCT03190213

About Pembrolizumab Injection

Pembrolizumab Injection is a phase 2 stage product being developed by Merck for Neuroendocrine Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT03190213. Target conditions include Neuroendocrine Tumors.

What happened to similar drugs?

6 of 16 similar drugs in Neuroendocrine Tumors were approved

Approved (6) Terminated (2) Active (9)

✅Everolimus (RAD001)NovartisApproved

✅Pasireotide + DiazoxideNovartisApproved

✅everolimusNovartisApproved

✅sunitinibPfizerApproved

✅lanreotide acetateIpsenApproved

✅lanreotide (Autogel formulation)IpsenApproved

🔄Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04808999	Phase 2	Active	May 11, 2021	Apr 30, 2029	Squamous Cell Carcinoma
NCT03190213	Phase 2	Terminated	Dec 4, 2017	Mar 11, 2019	Neuroendocrine Tumors

Competing Products

20 competing products in Neuroendocrine Tumors

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NET	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	27
[212Pb] VMT-α-NET	Perspective Therapeutics	Phase 1	27
Lenvatinib	Eisai	Phase 2	35
Abemaciclib	Eli Lilly	Phase 2	39
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.	Jiangsu Hengrui Medicine	Phase 3	47
Famitinib	Jiangsu Hengrui Medicine	Phase 2	27
68Ga-DOTATOC	Jiangsu Hengrui Medicine	Phase 3	47
Olaparib	AstraZeneca	Phase 2	27
Avelumab	Merck	Phase 1/2	32
Pembrolizumab	Merck	Phase 2	27
Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	35
Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab	Merck	Phase 1	33
Avelumab	Merck	Phase 2	35
Pembrolizumab + Lenvatinib	Merck	Phase 2	35
Avelumab	Merck	Phase 2	35
Pembrolizumab + Irinotecan + Paclitaxel	Merck	Phase 2	35
MK-0646	Merck	Phase 2	35
Lanreotide + Pembrolizumab	Merck	Phase 1/2	32